(AGENPARL) - Roma, 30 Settembre 2022 - (AGENPARL) – ven 30 settembre 2022 5.00 PM CEST / 30-Sep-2022 / Hansa Biopharma AB (STO:HNSA)
Hansa Biopharma: Increase of the number of shares and votes
Lund, Sweden, September 30, 2022. Hansa Biopharma AB “Hansa” or the “Company”, (Nasdaq Stockholm: HNSA), the pioneer enzyme technology for rare immunological conditions, today announces that the Company’s registered share capital and number of outstanding shares and votes have increased during the month of September 2022.
As previously announced on 8 September 2022, Hansa Biopharma’s board of directors resolved to issue 850,769 class C shares, by virtue of the authorizations by the annual general meeting held on 30 June 2022. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.
The purpose of the issue and repurchase was to ensure delivery of shares to employees and to secure potential social contributions arising as a result of the Company’s incentive programs in accordance with the resolutions from the annual general meeting held on 30 June 2022.
As of today, the total number of registered and outstanding shares of the Company amounts to 47,186,130, whereof 44,588,118 are ordinary shares and 2,598,012 are class C shares. As of today, the number of votes in the Company amounts to 44,847,919.2, and the registered share capital amounts to SEK 47,186,130.
This information is information that Hansa Biopharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on September 30, 2022, at 17:00 CEST
–ENDS—
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at [www.hansabiopharma.com](https://publish.ne.cision.com/l/tgqwszeme/hansabiopharma.com).
—————————————————————
This information was brought to you by Cision http://news.cision.com
Trending
- Consiglio dei ministri del 19 novembre 2026: il Governo decide di non impugnare la legge di bilancio della Regione Sardegna
- Manovra: Amendola (Pd), l’Italia non può fare la protagonista nel mondo e tagliare cooperazione e diplomazia
- GIORNALISMO: RUSSO (FI), CON AUGIAS E VIGORELLI SCOMPAIONO DUE PIONIERI CHE HANNO FATTO LA STORIA DELL’INFORMAZIONE
- Libia, Bengasi sfida Tripoli: Hammad minaccia l’autonomia finanziaria e amministrativa dell’Est
- Verso il 25 novembre, le iniziative del Tavolo Politiche di Genere
- Iscritti informativa urgente del Governo in merito ai recenti episodi di allarmi bomba negli istituti scolastici e agli attacchi hacker nella grande distribuzione alimentare
- Covid, Girelli (Pd): chiesta informativa urgente a Schillaci, commissione non può essere tribunale. Lettera scienziati rivendica indipendenza dalla politica
- MANOVRA. SCARPA (PD): TOGLIE 185 MILIONI AD ACCOGLIENZA COMUNI, CON NOSTRI EMENDAMENTI RISORSE DA ALBANIA A SAI
- In Municipio i bambini della scuola dell’infanzia San Vincenzo de’ Paoli
- COMUNICATO STAMPA CONTROLLI NOTTURNI DEI CARABINIERI E DELLA POLIZIA MUNICIPALE DENUNCIATA UNA COMMERCIANTE .doc